NVGN - Novogen Limited - American Depo

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.17
+0.18 (+6.17%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close2.99
Open3.16
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.00 - 3.20
52 Week Range3.00 - 3.20
Volume3,617
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE10 months ago

    Edison Issues ADR Update on Novogen (NVGN)

    LONDON, UK / ACCESSWIRE / September 11, 2017 / Novogen (NASDAQ: NVGN) is on track to commence a Phase II trial of GDC-0084 in glioblastoma in Q4 CY17, in line with previous guidance. It plans to meet with ...

  • PR Newswire11 months ago

    Australian cancer specialists may hold key to next advancement in ovarian cancer treatment

    SYDNEY, Aug. 30, 2017 /PRNewswire/ -- Three leading Australian cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy. Flinders Medical Centre in South Australia and Westmead Hospital in Sydney are also participating, along with leading US hospitals Peggy and Charles Stephenson Cancer Centre, and Mary Crowley Cancer Research Centre. "We've seen massive developments in other types of cancer but ovarian cancer has remained a challenge and, despite it being an unforgiving disease for women, treatment options have fallen behind as money and research are focused elsewhere," Associate Professor Coward said.

  • PR Newswire11 months ago

    GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc in October 2016, after completion of a phase I clinical trial in advanced glioma.

  • PR Newswire11 months ago

    GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc in October 2016, after completion of a phase I clinical trial in advanced glioma.

  • PR Newswire11 months ago

    Board Review of Business Operations and Governance

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

  • PR Newswire11 months ago

    Board Review of Business Operations and Governance

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

  • PR Newswire11 months ago

    Progress Update on Cantrixil(TM) (TRXE-002-1) Development

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Novogen commenced a phase I clinical trial of Cantrixil in ovarian cancer in December 2016.

  • PR Newswire11 months ago

    Progress Update on Cantrixil(TM) (TRXE-002-1) Development

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Novogen commenced a phase I clinical trial of Cantrixil in ovarian cancer in December 2016.